UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 107

Sortiert nach

Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols

European journal of haematology, 2020-08, Vol.105 (2), p.138-147

2020

Link zum Volltext

Verfügbarkeit prüfen

Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

Leukemia research, 2021-10, Vol.109, p.106612-106612, Article 106612

2021

Link zum Volltext

Verfügbarkeit prüfen

ALL-154: t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group

Clinical lymphoma, myeloma and leukemia, 2021-09, Vol.21, p.S270-S271

2021

Link zum Volltext

Verfügbarkeit prüfen

ALL-276: Complex Karyotype with ≥3 Cytogenetic Alterations is a New Marker of Worse Prognosis in Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Clinical lymphoma, myeloma and leukemia, 2020-09, Vol.20, p.S167-S168

2020

Link zum Volltext

Verfügbarkeit prüfen

Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT

Blood, 2014-12, Vol.124 (21), p.324-324

2014

Link zum Volltext

Verfügbarkeit prüfen

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK‐NUP214 shows a favourable outcome when performed in first complete remission

British journal of haematology, 2020-06, Vol.189 (5), p.920-925

2020

Link zum Volltext

Verfügbarkeit prüfen

AML-122 Midostaurin Maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: A “Real-Life” Multicenter Study

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S215

2022

Link zum Volltext

Verfügbarkeit prüfen

BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia

Blood, 2013-11, Vol.122 (21), p.2577-2577

2013

Link zum Volltext

Verfügbarkeit prüfen

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies

Molecular therapy, 2021-02, Vol.29 (2), p.636-644

2021

Link zum Volltext

Verfügbarkeit prüfen

Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic

British journal of haematology, 2024-03, Vol.204 (3), p.892-897

2024

Link zum Volltext

Verfügbarkeit prüfen

Clinic and therapeutic potential of non-coding RNAs in cancer

Translational cancer research, 2021-06, Vol.10 (6), p.3087-3089

2021

Link zum Volltext

Verfügbarkeit prüfen

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

Journal of clinical oncology, 2024-05, p.JCO2302175-JCO2302175

2024

Link zum Volltext

Verfügbarkeit prüfen

Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia

Blood, 2021-11, Vol.138 (Supplement 1), p.4799-4799

2021

Link zum Volltext

Verfügbarkeit prüfen

A Distinctive MicroRNA Signature Characterizes Acute Myeloid Leukemia with Translocation (8;16)(p11;p13) and MYST3-CREBBP Rearrangement

Blood, 2010-11, Vol.116 (21), p.230-230

2010

Link zum Volltext

Verfügbarkeit prüfen

The Distinctive MicroRNA Signature of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13)/MYST3-CREBBP Is Responsible for RET Overexpression and Is Regulated by Epigenetic Mechanisms

Blood, 2011-11, Vol.118 (21), p.2434-2434

2011

Link zum Volltext

Verfügbarkeit prüfen

DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1, FLT3-ITD and CEBPA

Blood, 2013-11, Vol.122 (21), p.1339-1339

2013

Link zum Volltext

Verfügbarkeit prüfen

Early T‐cell precursor lymphoblastic leukaemia: response to FLAG‐IDA and high‐dose cytarabine with sorafenib after initial refractoriness

British journal of haematology, 2019-05, Vol.185 (4), p.755-757

2019

Link zum Volltext

Verfügbarkeit prüfen

Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness

British journal of haematology, 2019, Vol.185 (4), p.755-757

2019

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients

Annals of hematology, 2010-12, Vol.89 (12), p.1233-1237

2010

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 super(V617F mutation)

Leukemia research, 2011-09, Vol.35 (9), p.1276-1278

2011

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 107

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(101)
Mit Volltextzugriff
(104)

Publikationsform

Artikel
(106)
Berichte
(1)

Sprache

Englisch
(107)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(39)
Clinical Lymphoma, Myeloma And Leukemia
(8)
Hemasphere
(7)
Leukemia Research
(6)
Annals Of Hematology
(4)
British Journal Of Haematology
(4)
Cancers
(4)
Haematologica
(3)
Leukemia & Lymphoma
(3)
Oncotarget
(3)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols

Adverse prognostic impact of complex karyotype (≥3 cytogenetic alterations) in adult T-cell acute lymphoblastic leukemia (T-ALL)

ALL-154: t(1;19)(q23;p13) TCF3-PBX1 May Not Be an Intermediate-Risk Subtype in Adult B-Cell Precursor Acute Lymphoblastic Leukemia Patients Treated With MRD-Oriented Protocols from the PETHEMA Group

ALL-276: Complex Karyotype with ≥3 Cytogenetic Alterations is a New Marker of Worse Prognosis in Adult T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia with t(6;9)(p23;q34);dek-NUP214 Is Followed By a Low Relapse Risk and Favorable Outcome in Early Phase- a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)

Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEK‐NUP214 shows a favourable outcome when performed in first complete remission

AML-122 Midostaurin Maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: A “Real-Life” Multicenter Study

BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia

Bone marrow VEGFC expression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival

CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies

Characteristics and long-term outcome in a large series of chronic myelomonocytic leukaemia patients including 104 formerly referred to as oligomonocytic

Characteristics and Outcome of Early T Cell Precursor ALL (ETP-ALL) Patients Treated with High-Risk Spanish Pethema Protocols

Clinic and therapeutic potential of non-coding RNAs in cancer

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

Correction to: A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia

A Distinctive MicroRNA Signature Characterizes Acute Myeloid Leukemia with Translocation (8;16)(p11;p13) and MYST3-CREBBP Rearrangement

The Distinctive MicroRNA Signature of Acute Myeloid Leukemia with Translocation t(8;16)(p11;p13)/MYST3-CREBBP Is Responsible for RET Overexpression and Is Regulated by Epigenetic Mechanisms

The division of chronic myelomonocytic leukemia (CMML)-1 into CMML-0 and CMML-1 according to 2016 World Health Organization (WHO) classification has no impact in outcome in a large series of patients from the Spanish group of MDS

DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1, FLT3-ITD and CEBPA

Early T‐cell precursor lymphoblastic leukaemia: response to FLAG‐IDA and high‐dose cytarabine with sorafenib after initial refractoriness

Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness

Efficacy and tolerability of hydroxyurea in the treatment of the hyperproliferative manifestations of myelofibrosis: results in 40 patients

Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2 super(V617F mutation)

Suchergebnisse filtern